Immunorizon

Bi and tri specific T-and NK-Cell Engagers for cancer therapy

Immunorizon is developing conditionally activated Tumor-Restricted T-and NK-Cell Engagers for cancer therapy. The company extends its pipeline and differentiate by using tri-specific constructs with additional tumor associated antigens and diverse engagers with both T-cells and NK-cells.

Immunorizon was acquired by Purple Biotech in 2023.